We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Disease Causes Recurrent Respiratory Infections

By LabMedica International staff writers
Posted on 29 Oct 2013
A rare genetic disease has been discovered which predisposes patients to severe respiratory infections and lung damage.

The genetic mutation identified affects the immune system, and physicians are hopeful that new drugs that are currently undergoing clinical trials to treat leukemia may also be effective in helping individuals with this debilitating disease.

International collaborating scientists led by those at the University of Cambridge (Cambridge, UK) examined genetic information from individuals who suffer from immunodeficiency and are predisposed to infections. More...
From this group, they identified a unique genetic mutation in 17 patients that suffer from severe respiratory infections and rapidly develop lung damage.

DNA samples were isolated from blood or peripheral blood mononuclear cells (PBMCs). Exome target enrichment was carried out using either the SureSelect kit (Agilent; Santa Clara, CA, USA) or the Truseq kit (Illumina; San Diego, CA, USA). The lipid kinase activity was determined using a modified membrane capture assay and many other complementary assays were also performed.

The team found that the genetic mutation increases activity of an enzyme called Phosphoinositide 3-Kinase δ (PI3Kδ). The enzyme is present in immune cells and regulates their function. However, constantly activated PI3Kδ impairs work of these immune cells, preventing them from responding efficiently to infection and providing long-lasting protection. Consequently, patients with this mutation have severe and recurrent infections.

Sergey Nejentsev, MD, PhD, a Wellcome Trust Senior Research Fellow from the University of Cambridge who led the study said, “We called this newly identified disease Activated PI3K-δ Syndrome (APDS) after the enzyme in the immune system that is affected by the genetic mutation. It is very important that doctors consider a possibility of APDS in their patients. A simple genetic test can tell if the patient has the mutation or not. We believe that now many more APDS patients will be identified all over the world.” The study was published on October 17, 2013, in the journal Science Express.

Related Links:

University of Cambridge
Agilent  
Illumina 



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Pipette
Accumax Smart Series
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.